56,060 research outputs found
USP11 role in colorectal cancer growing and metastatisation
No full textColo-Rectal Cancer (CRC) represents the third cause of cancer related death worldwide [1]. In the early stages (I-III) the approaches available for CRC treatment were represented by surgery followed or anticipated by chemo-radiotherapy. Unfortunately, a 20–25% of patients were diagnosed in advanced stages (IIIB-IV). In the past, for these patients the only therapeutic approach available was represented by chemotherapy. To date, technological innovation and the novel targeted therapies, such as antibodies against epidermal growth factor receptor (EGFR), showed their efficacy in a percentage of patients (about 50–60%) without mutation in RAS genes (KRAS, NRAS) and BRAF [2]. For this reason, a large part of metastatic CRC mCRC patients did not benefit of these fascinating therapeutic choice. In this setting, a better knowledge of the molecular mechanisms that could lead cancer development and survival represent an investigational hot – topic. Overall, there is a relevant unmet need in metastatic CRC (mCRC) patients with a constitute activation of MAPK pathway, due to the lack of target therapies for mCRC patients in this setting
Liquid biopsy as a follow-up tool: Comment on longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors
No full text
Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: Are the available data convincing?
No full textNon-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al. demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs)
Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers
No full textSpecial Issue: Next-Generation Sequencing in Tumor Diagnosis and Treatment II
No full textNext-generation sequencing (NGS) allows for the sequencing of multiple genes at a very high depth of coverage [...]
Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in-between
No full textTargeting immune checkpoints in non small cell lung cancer.
No full textCancers have the ability to disrupt immune response by interfering with adaptive immunity. Blocking checkpoint pathways has become a target for pharmacological research in lung cancer with particular focus on peptides PD-1 and CTLA-4. A number of immune check-point inhibitors (ICIs) targeting both PD-1 and CTLA-4 pathways are under investigation within clinical trials, of which Nivolumab, Pembrolizumab and Atezolizumab have already been approved for lung cancer treatment by both FDA and EMA. Employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC) ICIs have exhibited advantages in terms of overall survival and response rate with some responses being durable. Evaluating combinations of different inhibitors, dosing and sequencing within a multimodal therapy approach, together with better management of toxicity represents a new challenge for future research of therapy targeting immune check-points
- …
